Novartis drug is already approved. They are currently focusing on distribution and undertaking other studies to increase market share in the current treatable population. As I understand, Novartis are still interested in having their treatment offered earlier in the treatment process, which may open the door for Veyonda at some point in the future. Looks like a interesting 3rd and 4th quarter for holders.
- Forums
- ASX - By Stock
- NOX
- Ann: Noxopharm Corporate Presentation
Ann: Noxopharm Corporate Presentation, page-5
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NOX (ASX) to my watchlist
|
|||||
Last
8.6¢ |
Change
-0.007(7.53%) |
Mkt cap ! $25.13M |
Open | High | Low | Value | Volume |
9.2¢ | 9.2¢ | 8.3¢ | $35.92K | 415.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 7364 | 8.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.4¢ | 90189 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 7364 | 0.085 |
1 | 34896 | 0.084 |
3 | 34754 | 0.083 |
1 | 100000 | 0.081 |
1 | 8000 | 0.080 |
Price($) | Vol. | No. |
---|---|---|
0.094 | 90189 | 1 |
0.095 | 4200 | 1 |
0.096 | 50399 | 2 |
0.099 | 30800 | 2 |
0.100 | 312884 | 2 |
Last trade - 11.53am 15/08/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online